AnnLaCasceMD

PubMed

• A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.
  Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
  Journal of Clinical Oncology. 2024-12-07
• Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and L...
  Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib
  Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01
• A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treat...
  Eric Jacobsen, Ashley Plant, Robert Redd, Philippe Armand, Mikaela McDonough
  Leukemia & Lymphoma. 2024-12-01

Journal Articles

• Current Considerations in AYA Hodgkin Lymphoma  
  Jennifer L Crombie, Ann S LaCasce, British Journal of Haematology
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
  Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

• Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
  Ann S. LaCasce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Ann S. LaCasce, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019

Lectures

• How to Prepare Fellows for the Transition to Academia 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
• Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Training Program DirectorsÍ Workshop 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Career-Development Lunch Sessions 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Training Program DirectorsÍ Workshop 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematology Oncology Training Program Directors' Workshop 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• The Brigham Update in Medicine 
  Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 5/20/2013
• 2012 Highlights of ASH in North America (Atlanta, GA) 
  American Society of Hematology (ASH), Atlanta, Georgia - 1/27/2012
• Join now to see all

Other

• Overview of the approach to the adult survivor of classical Hodgkin lymphoma 
  LaCasce AS, Ng AK
  http://www.uptodate.com/contents/overview-of-the-approach-to-the-adult-survivor-of-classical-hodgkin
  UpToDate, Wolters Kluwer Health - 2013-03-29
• Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy 
  LaCasce AS, Burstein H, Meyerhardt JA, Castells MC
  http://www.uptodate.com/contents/infusion-reactions-to-therapeutic-monoclonal-antibodies-used-for-ca
  UpToDate, Wolters Kluwer Health - 2013-03-22
• Therapeutic use and toxicity of high-dose methotrexate 
  LaCasce AS
  http://www.uptodate.com/contents/therapeutic-use-and-toxicity-of-high-dose-methotrexate
  UpToDate, Wolters Kluwer Health - 2013-03-21
• Primary lymphoma of bone 
  LaCasce AS, Freedman AS
  http://www.uptodate.com/contents/primary-lymphoma-of-bone
  UpToDate, Wolters Kluwer Health - 2012-10-09
• Join now to see all